Source: International Congress 2015 – Emerging technologies for malignant pleural diseases management
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Theodora Agalioti (Patras, Greece), Theodora Agalioti, Anastasios Giannou, Antonia Marazioti, Nikolaos Kanellakis, Magda Spella, Ioannis Lillis, Dimitra Zazara, Konstantina Papadia, Sofia Antimisiaris, Dimitrios Kardamakis, Georgios Stathopoulos. Activated KRAS signaling triggers malignant pleural effusion. Eur Respir J 2015; 46: Suppl. 59, 5007

Member's Comments

No comment yet.

Related content which might interest you: Role of Dr-70 immunoassay in suspected malignant pleural effusion Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer Year: 2013 Predictive parameters of survival in malignant pleural effusion Source: International Congress 2015 – Malignant pleural effusions and mesothelioma Year: 2015 Elevated survivin is associated with a reduced survival in patients with malignant pleural effusion Source: Annual Congress 2013 –Fundamental biology of malignant pleural effusions Year: 2013 The utility of survivin mRNA as a diagnostic biomarker in lung cancer with malignant pleural effusion Source: Annual Congress 2013 –Fundamental biology of malignant pleural effusions Year: 2013 Detection of EpCAM-positive microparticles in pleural fluid: A new approach for the diagnosis of the tumoral origin of pleural effusions Source: International Congress 2015 – Emerging technologies for malignant pleural diseases management Year: 2015 Survival of non small cell lung carcinoma patients with malignant pleural effusions Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Malignant pleural effusion (MPE) as debut of cancer Source: International Congress 2015 – Malignant pleural effusions and mesothelioma Year: 2015 Lent score validation on patients with malignant pleural effusion Source: International Congress 2016 – Malignant pleural disease: diagnosis and management Year: 2016 Malignant pleural effusion as the initial manifestation of gynecological malignancies Source: International Congress 2016 – Malignant pleural disease: diagnosis and management Year: 2016 Recruitment and phenotypic characteristics of interleukin 9−Producing CD4+ T cells in malignant pleural effusion Source: Annual Congress 2013 –Fundamental biology of malignant pleural effusions Year: 2013 LATE-BREAKING ABSTRACT: A proteomic study of benign and malignant pleural effusions Source: International Congress 2015 – Malignant pleural effusions and mesothelioma Year: 2015 The protein DJ-1 in malignant pleural effusions due to lung cancer: Levels and correlations with oxidative stress biomarkers Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 A requirement for kras signaling in malignant pleural effusion Source: Annual Congress 2013 –Fundamental biology of malignant pleural effusions Year: 2013 Diagnostic value of pleural fluid angiopoietin-2 (Ang-2) levels, to differentiate malignant pleural effusions from benign pleural effusions Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016 Solitary fibrous tumour of the pleural: Two malignant cases Source: International Congress 2015 – Mediastinal tumors, malignant pleural mesothelioma and other rare tumors Year: 2015 Predictive value of pro-inflammatory cytokine and pro-angiogenic factor in differentiating malignant from benign exudative effusion Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies Year: 2014 Pleural mesothelioma with solitary simultaneous subcutaneous tissue metastasis of the abdominal wall at diagnosis - First clinical documentation Source: Annual Congress 2013 –Other thoracic tumours, particular circumstances and rare cases Year: 2013 Efficacy of recombinant adenoviral human p53 gene in treatment of lung cancer-mediated pleural effusion Source: International Congress 2015 – Emerging technologies for malignant pleural diseases management Year: 2015 Ideal volume sampling in the diagnosis of malignant pleural effusions. Just how much is really enough? Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013 Risk of occult pleural infection in patients with malignant effusions Source: Annual Congress 2013 –Diagnosis and management of pleural and mediastinal diseases Year: 2013